Corona Remedies Ltd
- Market Cap ₹ 6,495 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 43.4
- Book Value ₹
- Dividend Yield %
- ROCE 31.5 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 20.4% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 25.0%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | |
| 444 | 509 | 471 | 600 | 756 | 859 | 956 | |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 |
| OPM % | 13% | 15% | 18% | 3% | 14% | 15% | 20% |
| 3 | 3 | 5 | 7 | 7 | 5 | 5 | |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 | 118 | 198 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% |
| 35 | 59 | 70 | -0 | 85 | 90 | 149 | |
| EPS in Rs | |||||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 25% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 538% |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 24% |
| Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 |
| 13 | 47 | 50 | 34 | 28 | 159 | 86 | |
| 71 | 94 | 144 | 157 | 159 | 191 | 237 | |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 |
| 80 | 81 | 164 | 162 | 185 | 384 | 370 | |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 |
| 200 | 278 | 330 | 321 | 314 | 301 | 348 | |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 19 | 43 | 79 | 98 | 103 | 157 | 190 | |
| -23 | -50 | -102 | -66 | -50 | -267 | -84 | |
| 4 | 30 | 0 | -30 | -45 | 99 | -107 | |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 |
| ROCE % | 30% | 27% | 1% | 29% | 25% | 31% |
Documents
Annual reports
No data available.